---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-022852"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T19:51:26.724504+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Insmed Q1 revenue up 23% to $65.2M; net loss widens to $159.8M; pipeline on track

## Summary
- ARIKAYCE global revenue $65.2M, up 23% YoY; U.S. net sales $49.1M, Japan $13.2M.
- Net loss $159.8M ($1.17/share) vs $94.6M ($0.80) in Q1 2022; R&D spend rose to $127.9M.
- Cash and securities $999M at March 31, 2023, down from $1.15B at Dec 31, 2022.
- Phase 3 ASPEN enrollment completed (1,700+ patients); topline data expected Q2 2024.
- Reaffirmed FY2023 ARIKAYCE revenue guidance $285M-$300M; appointed Makoto Nakamura GM Japan.

## SEC filing metadata
- accession: 0001140361-23-022852
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/0001140361-23-022852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/brhc20052467_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-022852
- JSON: https://secwatch.observer/filing/0001140361-23-022852.json
- Plain text: https://secwatch.observer/filing/0001140361-23-022852.txt

## Key facts
- Earnings Releases
  INSMED Inc reported the first quarter ended March 31, 2023 results: revenue $65.2 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $65.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the first quarter ended March 31, 2023, was $65.2 million, reflecting 23% year-over-year growth compared to total revenue of $53.1 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/0001140361-23-022852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.